Abstract 944: Pre-clinical activity of the Wnt pathway inhibitor RXC004 in combination with MAPK pathway inhibitors in GI cancer models

Simon A. Woodcock(Bio-Medical Science (South Korea)), C. W. Phillips, Emma L. Bishop(University of Birmingham), Eimear Flanagan, Catherine Eagle, Richard Armer(Redx Pharma (United Kingdom)), Inder Bhamra(Redx Pharma (United Kingdom)), Dorottya Keppel(4D Pharma (United Kingdom)), Clifford D. Jones(4D Pharma (United Kingdom)), Jane Robertson(Cancer Research UK), James Kelly(Redx Pharma (United Kingdom))
Cancer Research
March 22, 2024
10.1158/1538-7445.am2024-944
Cited by 1

Related Papers

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
|British Journal of Cancer|2018|233
Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
|Journal of Clinical Oncology|2012|210
Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma
|British Journal of Cancer|2000|208